Search Result

Results for "

Sitagliptin

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Autophagy (3) Bacterial (1) Biochemical Assay Reagents (1) Dipeptidyl Peptidase (18) Drug Intermediate (5) Endogenous Metabolite (11) ERK (11) Free Fatty Acid Receptor (1) GLP Receptor (11) Isotope-Labeled Compounds (5) PKA (11) Reference Standards (7)
By Research Areas:	Cardiovascular Disease (1) Infection (1) Metabolic Disease (20)
Oligonucleotides:	Fillers (1)

Inhibitors & Agonists

Biochemical Assay Reagents

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13749

*Sitagliptin* Maximum Cited Publications 26 Publications Verification MK-0431	Dipeptidyl Peptidase GLP Receptor Endogenous Metabolite PKA ERK	Metabolic Disease
Sitagliptin (MK-0431) is an orally active and highly selective DPP4 inhibitor with an IC₅₀ value of 19 nM. Sitagliptin blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin can be used for the study of 1-type and 2-type diabetes .

HY-Z4291

Sitagliptin impurity 2	Drug Intermediate	Others
Sitagliptin impurity 2 is an impurity of Sitagliptin (HY-13749).

HY-Z0357

Sitagliptin impurity 5	Drug Intermediate	Others
Sitagliptin impurity 5 is an impurity of Sitagliptin (HY-13749).

HY-Z2765

Sitagliptin impurity 4	Drug Intermediate	Others
Sitagliptin impurity 4 is an impurity of Sitagliptin (HY-13749).

HY-Z4409

Sitagliptin impurity 6	Drug Intermediate	Others
Sitagliptin impurity 12 is an impurity of Sitagliptin (HY-13749).

HY-Z3877

Sitagliptin impurity 1	Drug Intermediate	Others
Sitagliptin impurity 1 is an impurity of Sitagliptin (HY-13749).

HY-13749B

Sitagliptin phosphate monohydrate Maximum Cited Publications 26 Publications Verification MK-0431 phosphate monohydrate	Dipeptidyl Peptidase GLP Receptor Endogenous Metabolite PKA ERK	Metabolic Disease
Sitagliptin (MK-0431) phosphate monohydrate is an orally active and highly selective DPP4 inhibitor with an IC₅₀ value of 19 nM. Sitagliptin phosphate monohydrate blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin phosphate monohydrate can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin phosphate monohydrate shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin phosphate monohydrate can be used for the study of 1-type and 2-type diabetes .

HY-13749A

Sitagliptin phosphate Maximum Cited Publications 26 Publications Verification MK-0431 phosphate	Dipeptidyl Peptidase GLP Receptor Endogenous Metabolite PKA ERK	Metabolic Disease
Sitagliptin (MK-0431) phosphate is an orally active and highly selective DPP4 inhibitor with an IC₅₀ value of 19 nM. Sitagliptin phosphate blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin phosphate can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin phosphate shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin phosphate can be used for the study of 1-type and 2-type diabetes .

HY-147401

Sitagliptin fenilalanil 1 Publications Verification	Dipeptidyl Peptidase	Metabolic Disease
Sitagliptin fenilalanil is a dipeptidyl aminopeptidase 4 (DPP-4) inhibitor .

HY-13749E

Sitagliptin hydrochloride MK-0431 hydrochloride	Dipeptidyl Peptidase GLP Receptor Endogenous Metabolite PKA ERK	Metabolic Disease
Sitagliptin (MK-0431) hydrochloride is an orally active and highly selective DPP4 inhibitor with an IC₅₀ value of 19 nM. Sitagliptin hydrochloride blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin hydrochloride can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin hydrochloride shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin hydrochloride can be used for the study of 1-type and 2-type diabetes .

HY-147401A

Sitagliptin fenilalanil hydrochloride 1 Publications Verification	Dipeptidyl Peptidase	Metabolic Disease
Sitagliptin fenilalanil hydrochloride is a dipeptidyl aminopeptidase 4 (DPP-4) inhibitor .

HY-13749R

Sitagliptin (Standard) MK-0431 (Standard)	Reference Standards Dipeptidyl Peptidase GLP Receptor Endogenous Metabolite PKA ERK	Metabolic Disease
Sitagliptin (Standard) is the analytical standard of Sitagliptin (HY-13749). This product is intended for research and analytical applications. Sitagliptin is an orally active and highly selective DPP4 inhibitor with an IC₅₀ value of 19 nM. Sitagliptin blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin can be used for the study of 1-type and 2-type diabetes.

HY-13749AR

Sitagliptin phosphate (Standard) MK-0431 phosphate (Standard)	Reference Standards Dipeptidyl Peptidase GLP Receptor Endogenous Metabolite PKA ERK	Metabolic Disease
Sitagliptin (MK-0431) phosphate (Standard) is the analytical standard of Sitagliptin phosphate (HY-13749A). This product is intended for research and analytical applications. Sitagliptin phosphate is an orally active and highly selective DPP4 inhibitor with an IC₅₀ value of 19 nM. Sitagliptin phosphate blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin phosphate can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin phosphate shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin phosphate can be used for the study of 1-type and 2-type diabetes.

HY-13749BR

Sitagliptin phosphate monohydrate (Standard) MK-0431 phosphate monohydrate (Standard)	Reference Standards Dipeptidyl Peptidase GLP Receptor Endogenous Metabolite PKA ERK	Metabolic Disease
Sitagliptin (MK-0431) phosphate monohydrate (Standard) is the analytical standard of Sitagliptin phosphate monohydrate (HY-13749B). This product is intended for research and analytical applications. Sitagliptin phosphate monohydrate is an orally active and highly selective DPP4 inhibitor with an IC₅₀ value of 19 nM. Sitagliptin phosphate monohydrate blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin phosphate monohydrate can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin phosphate monohydrate shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin phosphate monohydrate can be used for the study of 1-type and 2-type diabetes.

HY-13749AS

Sitagliptin-d4 phosphate MK-0431-d₄ phosphate	Dipeptidyl Peptidase GLP Receptor Endogenous Metabolite PKA ERK	Metabolic Disease
Sitagliptin-d₄ phosphate (MK-0431-d₄) is the deuterium labeled Sitagliptin phosphate (HY-13749A). Sitagliptin phosphate is an orally active and highly selective DPP4 inhibitor with an IC₅₀ value of 19 nM. Sitagliptin phosphate blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin phosphate can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin phosphate shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin phosphate can be used for the study of 1-type and 2-type diabetes.

HY-13749S3

Sitagliptin-d6 MK-0431-d₆	Isotope-Labeled Compounds Dipeptidyl Peptidase GLP Receptor Endogenous Metabolite PKA ERK	Metabolic Disease
Sitagliptin-d₆ (MK-0431-d₆) is deuterium labeled Sitagliptin (HY-13749). Sitagliptin is an orally active and highly selective DPP4 inhibitor with an IC₅₀ value of 19 nM. Sitagliptin blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin can be used for the study of 1-type and 2-type diabetes.

HY-13749S2

Sitagliptin-d4 MK-0431-d₄	Isotope-Labeled Compounds Dipeptidyl Peptidase GLP Receptor Endogenous Metabolite PKA ERK	Metabolic Disease
Sitagliptin-d₄ (MK-0431-d₄) is deuterium labeled Sitagliptin (HY-13749). Sitagliptin is an orally active and highly selective DPP4 inhibitor with an IC₅₀ value of 19 nM. Sitagliptin blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin can be used for the study of 1-type and 2-type diabetes.

HY-13749S1

Sitagliptin-d4 hydrochloride MK-0431-d₄ hydrochloride	Isotope-Labeled Compounds Dipeptidyl Peptidase GLP Receptor Endogenous Metabolite PKA ERK	Metabolic Disease
Sitagliptin-d₄ hydrochloride is the deuterium labeled Sitagliptin hydrochloride (HY-13749E). Sitagliptin hydrochloride is an orally active and highly selective DPP4 inhibitor with an IC₅₀ value of 19 nM. Sitagliptin hydrochloride blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin hydrochloride can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin hydrochloride shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin hydrochloride can be used for the study of 1-type and 2-type diabetes.

HY-Z4409R

Sitagliptin impurity 6 (Standard)	Reference Standards
(R)-Ethyl 3-amino-4-(2,4,5-trifluorophenyl)butanoate (Sitagliptin Impuruity) (Standard) is the analytical standard of (R)-Ethyl 3-amino-4-(2,4,5-trifluorophenyl)butanoate (Sitagliptin Impuruity). This product is intended for research and analytical applications.

HY-Z2765R

Sitagliptin impurity 4 (Standard)	Reference Standards
(R)-3-((tert-butoxycarbonyl)amino)-4-(2,5-difluorophenyl)butanoic acid (Sitagliptin Impurity） (Standard) is the analytical standard of (R)-3-((tert-butoxycarbonyl)amino)-4-(2,5-difluorophenyl)butanoic acid (Sitagliptin Impurity）. This product is intended for research and analytical applications.

HY-Z0357R

Sitagliptin impurity 5 (Standard)	Reference Standards
(R)-3-Amino-4-(2,4,5-trifluorophenyl)butanoic acid (Standard) is the analytical standard of (R)-3-Amino-4-(2,4,5-trifluorophenyl)butanoic acid. This product is intended for research and analytical applications.

HY-131250

N-Boc-Sitagliptin	Dipeptidyl Peptidase	Metabolic Disease
N-Boc-Sitagliptin is an intermediate in the synthesis of the dipeptidyl peptidase 4 (DPP-4) inhibitor Sitagliptin (HY-13749).

HY-Z3637

*(–)-Sitagliptin* carbamoyl glucuronide**	Dipeptidyl Peptidase	Metabolic Disease
(–)-Sitagliptin carbamoyl glucuronide is a minor metabolite of the dipeptidyl peptidase 4 (DPP-4) inhibitor Sitagliptin (HY-13749).

HY-13749C

*(S)-Sitagliptin* phosphate** (S)-MK-0431 phosphate	Dipeptidyl Peptidase Autophagy	Metabolic Disease
(S)-Sitagliptin phosphate is the less active S-enantiomer of Sitagliptin phosphate. Sitagliptin phosphate (MK-0431 phosphate) is a potent inhibitor of DPP4 with an IC₅₀ of 19 nM in Caco-2 cell extracts .

HY-Z3334S

*N-Acetyl Sitagliptin-d3*	Isotope-Labeled Compounds	Others
N-Acetyl Sitagliptin-d₃ is the deuterium labeled N-Acetyl Sitagliptin .

HY-13749CR

*(S)-Sitagliptin* phosphate (Standard)** (S)-MK-0431 phosphate (Standard)	Reference Standards Dipeptidyl Peptidase Autophagy	Metabolic Disease
(S)-Sitagliptin (phosphate) (Standard) is the analytical standard of (S)-Sitagliptin (phosphate). This product is intended for research and analytical applications. (S)-Sitagliptin phosphate is the less active S-enantiomer of Sitagliptin phosphate. Sitagliptin phosphate (MK-0431 phosphate) is a potent inhibitor of DPP4 with an IC50 of 19 nM in Caco-2 cell extracts .

HY-13749D

(Rac)-Sitagliptin (Rac)-MK-0431	Autophagy Dipeptidyl Peptidase	Metabolic Disease
(Rac)-Sitagliptin is an isoform of Sitagliptin (HY-13749), which is a potent and orally active inhibitor of DPP4 with an IC₅₀ of 19 nM in Caco-2 cell extracts .

HY-132489S

*(Rac)-Sitagliptin-d4* (Rac)-MK-0431-d₄	Isotope-Labeled Compounds	Others
(Rac)-Sitagliptin-d₄ is the deuterium labeled (Rac)-Sitagliptin .

HY-123871

AS2575959 sodium	Free Fatty Acid Receptor	Metabolic Disease
AS2575959 (sodium) is an agonist of GPR40. AS2575959 (sodium) can enhance glucose metabolism and has synergic effect with Sitagliptin (HY-13749) on insulin as well as incretin secretion. AS2575959 (sodium) can be studied in research on type 2 diabetes .

HY-W134326

Polydextrose	Bacterial	Infection Cardiovascular Disease Metabolic Disease
Polydextrose is an orally active prebiotic. Polydextrose promotes the growth of Pediococcus pentosaceus ATCC 43200. Polydextrose reduces cholesterol and synergistically lowers blood sugar with Sitagliptin (HY-13749). Currently, it is mainly used in the research of diseases such as hyperlipidemia, type 2 diabetes, and postoperative iron deficiency anemia .

HY-76120

3-Trifluoromethyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine hydrochloride Intermediate Ⅰ of Sitagliptin phosphate	Biochemical Assay Reagents	Others
3-Trifluoromethyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine (hydrochloride) is a biochemical reagent that can be used as a biological material or organic compound for life science related research.

Cat. No.	Product Name	Type

HY-W134326

Polydextrose	Biochemical Assay Reagents
Polydextrose is an orally active prebiotic. Polydextrose promotes the growth of Pediococcus pentosaceus ATCC 43200. Polydextrose reduces cholesterol and synergistically lowers blood sugar with Sitagliptin (HY-13749). Currently, it is mainly used in the research of diseases such as hyperlipidemia, type 2 diabetes, and postoperative iron deficiency anemia .

HY-76120

3-Trifluoromethyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine hydrochloride Intermediate Ⅰ of Sitagliptin phosphate	Biochemical Assay Reagents
3-Trifluoromethyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine (hydrochloride) is a biochemical reagent that can be used as a biological material or organic compound for life science related research.

Cat. No.	Product Name	Chemical Structure

HY-13749AS

Sitagliptin-d4 phosphate
Sitagliptin-d₄ phosphate (MK-0431-d₄) is the deuterium labeled Sitagliptin phosphate (HY-13749A). Sitagliptin phosphate is an orally active and highly selective DPP4 inhibitor with an IC₅₀ value of 19 nM. Sitagliptin phosphate blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin phosphate can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin phosphate shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin phosphate can be used for the study of 1-type and 2-type diabetes.

Sitagliptin-d4 phosphate

Sitagliptin-d₄ phosphate (MK-0431-d₄) is the deuterium labeled Sitagliptin phosphate (HY-13749A). Sitagliptin phosphate is an orally active and highly selective DPP4 inhibitor with an IC₅₀ value of 19 nM. Sitagliptin phosphate blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin phosphate can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin phosphate shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin phosphate can be used for the study of 1-type and 2-type diabetes.

HY-13749S1

Sitagliptin-d4 hydrochloride
Sitagliptin-d₄ hydrochloride is the deuterium labeled Sitagliptin hydrochloride (HY-13749E). Sitagliptin hydrochloride is an orally active and highly selective DPP4 inhibitor with an IC₅₀ value of 19 nM. Sitagliptin hydrochloride blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin hydrochloride can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin hydrochloride shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin hydrochloride can be used for the study of 1-type and 2-type diabetes.

Sitagliptin-d4 hydrochloride

Sitagliptin-d₄ hydrochloride is the deuterium labeled Sitagliptin hydrochloride (HY-13749E). Sitagliptin hydrochloride is an orally active and highly selective DPP4 inhibitor with an IC₅₀ value of 19 nM. Sitagliptin hydrochloride blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin hydrochloride can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin hydrochloride shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin hydrochloride can be used for the study of 1-type and 2-type diabetes.

HY-13749S3

Sitagliptin-d6
Sitagliptin-d₆ (MK-0431-d₆) is deuterium labeled Sitagliptin (HY-13749). Sitagliptin is an orally active and highly selective DPP4 inhibitor with an IC₅₀ value of 19 nM. Sitagliptin blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin can be used for the study of 1-type and 2-type diabetes.

Sitagliptin-d6

Sitagliptin-d₆ (MK-0431-d₆) is deuterium labeled Sitagliptin (HY-13749). Sitagliptin is an orally active and highly selective DPP4 inhibitor with an IC₅₀ value of 19 nM. Sitagliptin blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin can be used for the study of 1-type and 2-type diabetes.

HY-13749S2

Sitagliptin-d4
Sitagliptin-d₄ (MK-0431-d₄) is deuterium labeled Sitagliptin (HY-13749). Sitagliptin is an orally active and highly selective DPP4 inhibitor with an IC₅₀ value of 19 nM. Sitagliptin blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin can be used for the study of 1-type and 2-type diabetes.

Sitagliptin-d4

Sitagliptin-d₄ (MK-0431-d₄) is deuterium labeled Sitagliptin (HY-13749). Sitagliptin is an orally active and highly selective DPP4 inhibitor with an IC₅₀ value of 19 nM. Sitagliptin blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin can be used for the study of 1-type and 2-type diabetes.

HY-Z3334S

*N-Acetyl Sitagliptin-d3*
N-Acetyl Sitagliptin-d₃ is the deuterium labeled N-Acetyl Sitagliptin .

HY-132489S

*(Rac)-Sitagliptin-d4*
(Rac)-Sitagliptin-d₄ is the deuterium labeled (Rac)-Sitagliptin .

Cat. No.	Product Name		Classification

HY-W134326

Polydextrose		Fillers
Polydextrose is an orally active prebiotic. Polydextrose promotes the growth of Pediococcus pentosaceus ATCC 43200. Polydextrose reduces cholesterol and synergistically lowers blood sugar with Sitagliptin (HY-13749). Currently, it is mainly used in the research of diseases such as hyperlipidemia, type 2 diabetes, and postoperative iron deficiency anemia .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: